SELLAS reports positive Phase 2a topline data for SLS009 in AML; first patient achieved complete response

SELLAS Life Sciences Group, Inc.

First of 5 enrolled r/r AML patients achieved complete response, remains alive in 5th month of treatment.
All 5 patients alive at last follow-up; 4 continue treatment; anti-leukemic effects seen in all.
No significant safety issues observed at 45 mg dose level; median OS for venetoclax-failure AML is ~2.5 months.
SLS009 is first CDK9 inhibitor to achieve CR in combination with AZA/VEN in venetoclax-resistant AML.
Topline data for 60 mg dose expected later this quarter; multiple registrational opportunities cited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.